With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.
The resulting compound (190 mg, 0.600 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (110 mg, 0.600 mmol) to afford N-[(1S)-1-{[4-(cyclohexyloxy)piperidin-1-yl]carbonyl}-2-methylpropyl]-3-hydroxyquinoxaline-2-carboxamide (219 mg, yield 81%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.81 (1H, brs), 9.45 (1H, t, J=8.3 Hz), 7.86 (1H, d, J=8.3 Hz), 7.63 (1H, t, J=7.5 Hz), 7.39-7.36 (1H, m), 4.86 (1H, dd, J=16.1 Hz, 9.3 Hz), 3.95-3.88 (2H, m), 3.70-3.63 (1H, m), 3.39-3.27 (3H, m), 3.19-3.06 (1H, m), 2.51-2.49 (4H, m), 1.92-1.11 (11H, m), 0.95-0.92 (6H, m). IR (ATR) cm-1: 2930, 1690, 1640, 1530, 1475, 1450, 1090. MS (ESI, m/z): 455 (M+H)+. Anal. Calcd for C25H34N4O4: C, 66.06; H, 7.54; N, 12.33. Found: C, 65.77; H, 7.47; N, 12.33., 1204-75-7
As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.
Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider